Pharmaceuticals News and Research

RSS

People with chronic inflammatory conditions may benefit from mindfulness meditation

People suffering from chronic inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and asthma - in which psychological stress plays a major role - may benefit from mindfulness meditation techniques, according to a study by University of Wisconsin-Madison neuroscientists with the Center for Investigating Healthy Minds at the Waisman Center.

17 Jan 2013

UCI study identifies transgenerational effects of tributyltin

Exposing pregnant mice to low doses of the chemical tributyltin - which is used in marine hull paint and PVC plastic - can lead to obesity for multiple generations without subsequent exposure, a UC Irvine study has found.

17 Jan 2013

AVEO commences underwritten public offering of shares of common stock

AVEO Pharmaceuticals, Inc. today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO.

17 Jan 2013

Tamoxifen can counteract some pathologic features in mouse model of DMD

A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.

16 Jan 2013

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants.

From Thermo Fisher Scientific Inc. 16 Jan 2013

Study identifies 24 new copy number variants linked with autism

University of Utah (the U) researchers, in collaboration with several groups from around the country, published a paper on Monday, Jan. 14, 2013, following one of the biggest studies of its kind, that extends our understanding of genes related to autism spectrum diseases (ASDs) and advances methods for early detection and treatment.

16 Jan 2013

Zimbabwe continues to face medicine shortages, stock-outs, PlusNews reports

"Chronic shortages of generic and antiretroviral drugs, stock-outs, high medication costs, and long distances to clinics are some of the hurdles people face in their quest to access essential medicines in Zimbabwe," PlusNews reports.

16 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Today, AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer's disease and schizophrenia.

16 Jan 2013

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Pfizer Inc. today announced that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).

16 Jan 2013

p53 activation suppresses malic enzyme expression and leads to senescence in pre-cancerous cells

It is perhaps impossible to overstate the importance of the tumor suppressor gene p53. It is the single most frequently mutated gene in human tumors. p53 keeps pre-cancerous cells in check by causing cells, among other things, to become senescent - aging at the cellular level. Loss of p53 causes cells to ignore the cellular signals that would normally make mutant or damaged cells die or stop growing.

16 Jan 2013

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

11 Jan 2013

Longer looks: A key Hagel mission is to cut military health costs; Medical lessons from a mother's death; How they price - and how we pay for -a $300,000 medicine

As David Brooks and Paul Wolfowitz and many others have shown, it's easy to frame our messy fiscal conundrum in these simple terms of guns vs. butter, or rather, guns vs grandma's buttery-yellow, super-pricey heart medication.

11 Jan 2013

New guidelines to help fast track radiation oncology drug development

Researchers from the translational research program of the National Cancer Institute and the Radiation Therapy Oncology Therapy Group have developed new guidelines to help fast track the clinical development of targeted cancer drugs in combination with radiation therapy.

11 Jan 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

High-fiber diets may control progression of prostate cancer

A high-fiber diet may have the clinical potential to control the progression of prostate cancer in patients diagnosed in early stages of the disease.

10 Jan 2013

Glycan released by parasites might help treat metabolic disorders associated with obesity

On the list of undesirable medical conditions, a parasitic worm infection surely ranks fairly high. Although modern pharmaceuticals have made them less of a threat in some areas, these organisms are still a major cause of disease and disability throughout much of the developing world.

9 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Wockhardt receives final FDA approval for Lamotrigine to treat epilepsy

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy.

9 Jan 2013

Pharmaceuticals News and Research

People with chronic inflammatory conditions may benefit from mindfulness meditation

UCI study identifies transgenerational effects of tributyltin

AVEO commences underwritten public offering of shares of common stock

Tamoxifen can counteract some pathologic features in mouse model of DMD

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Study identifies 24 new copy number variants linked with autism

Zimbabwe continues to face medicine shortages, stock-outs, PlusNews reports

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

p53 activation suppresses malic enzyme expression and leads to senescence in pre-cancerous cells

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Longer looks: A key Hagel mission is to cut military health costs; Medical lessons from a mother's death; How they price - and how we pay for -a $300,000 medicine

New guidelines to help fast track radiation oncology drug development

Scientists develop playbook to end devastating impact of fibrotic diseases

High-fiber diets may control progression of prostate cancer

Glycan released by parasites might help treat metabolic disorders associated with obesity

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Wockhardt receives final FDA approval for Lamotrigine to treat epilepsy

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence